China National Biotec Group is set to start clinical trials of its two Omicron-specific vaccine candidates
Scientists say vaccines based on older strains show weaker activity to neutralise the highly transmissible Omicron variant.
Two Covid-19 vaccine candidates developed by units of China National Biotec Group to target the Omicron variant have been approved for clinical trials as boosters in Hong Kong. The two candidates, both containing inactivated or "killed" Omicron virus and similar to the two Sinopharm vaccines in use in China, will be tested in adults who have already received two or three vaccine doses, CNBG said in a statement on Saturday.
Scientists worldwide are racing to study upgraded injections against Omicron, as data indicated that antibodies elicited by vaccines based on older strains show weaker activity to neutralise the highly transmissible variant.It did not specify which vaccine products the trial participants would have received before taking the experimental booster, or how many subjects would be recruited.
While the fourth dose did restore antibody levels to around the peak levels that followed the third dose, researchers said new vaccines would offer a better alternative as future boosters.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Pfizer may have COVID-19 booster that addresses omicron, other variants by fallBy this fall, Pfizer and its partner BioNTech could potentially have a COVID-19 booster that specifically addresses the omicron variant as well as its subvariants and other known strains of the virus, CEO Albert Bourla said during a panel.
Weiterlesen »
Pfizer Says Covid-19 Booster in Children Ages 5 to 11 Sparked Immune Response Against OmicronA booster shot of the Pfizer-BioNTech Covid vaccine in children ages 5 to 11 significantly increased antibody levels against the Omicron variant as well as against the initial strain it was designed to fight, a late-stage study found.
Weiterlesen »
Omicron BA.2 Is Advancing, but Covid-19 Hospitalizations Stay MutedThe Omicron BA.2 variant has dominated new infections in the U.S. for weeks without setting off a major surge so far, raising hopes among some public-health experts that the nation might dodge a more significant hit
Weiterlesen »
Omicron-specific Sinopharm COVID vaccine candidates cleared for clinical trialTwo COVID-19 vaccine candidates developed by units of China National Biotec Group (CNBG) to target the Omicron variant were approved for clinical trials as boosters in Hong Kong, the Sinopharm subsidiary said on Saturday.
Weiterlesen »
NY Issues COVID Warning as New Omicron Subvariants Fuel ‘Significant Community Spread'Two omicron subvariants of the highly transmissible BA.2 strain are fueling “significant community spread” in parts of New York, state health officials say, calling their data the first charting such subvariant transmission rates in the U.S. The emergence of subvariants BA.2.12 and BA.2.12.1 both sublineages of the BA.2, strain that some have described as the most contagious version of COVID…
Weiterlesen »